© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
July 28th 2021, 11:00pm
Opdivo was granted an accelerated approval for patients with hepatocellular carcinoma, but the indication was pulled after follow-up data failed to show that the agent improved survival over another drug.
July 12th 2021, 3:00pm
Patients whose disease contained the osteopontin protein tended to have more aggressive liver cancer that did not respond to treatment.
July 9th 2021, 9:00pm
Screening and diagnostic procedures for liver cancer as well as transplant programs and curative/palliative treatments were modified or delayed due to the COVID-19 pandemic, a new survey says.
July 8th 2021, 1:00pm
Most people surveyed knew about the link between alcohol and liver cancer, but far fewer knew that drinking could increase breast cancer risk, too.
June 15th 2021, 9:00pm
Treatment with the combination of Stivarga and Bavencio was associated with minor anti-tumor activity in patients with advanced, heavily pretreated biliary tract solid tumors.
June 8th 2021, 8:00pm
Onivyde combined with a chemotherapy agent and a chemotherapy-protective drug should be used as a second-line treatment option in patients with metastatic liver cancer, according to an expert.
June 3rd 2021, 1:00pm
The Food and Drug Administration has had a busy couple of weeks, approving several agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
May 29th 2021, 1:52pm
The FDA approved a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other arrangement.
May 26th 2021, 9:00pm
The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.
May 10th 2021, 3:00pm
Twenty percent of patients with resectable hepatocellular carcinoma had a significant amount of cell death when receiving Libtayo before surgical intervention.
3 Ways to Get Cancer Off Your Back
Pregnant Women With Previous or Current Cancer Diagnoses May Experience More Complications During Delivery
Navigating the Unknown of Rare Cancers
Playing With House Money: Defying Cancer Odds